With all the excitement surrounding kevetrin and prurisol, i cant help but wonder what will happen with KM391, the autism compound that has shown so much promise in studies so far. This could be a blockbuster in its own right, but with it taking a backseat so that kevetrin and prurisol could be rapidly developed, i wonder if we would be short changed if a buy out happens too soon and this compound doesnt get a chance to prove itself in trials. Thoughts?